retatrutide heart rate increase: causes, risks and evidence Higher resting heart rate concerns

Its effectiveness is linked to its strong binding affinity to the GLP-1 receptor and its long half-life, enabling convenient once-weekly dosing

Eli Lilly is currently evaluating Mounjaro in clinical trials for heart failure (HF) patients, potentially expanding its use in type 2 diabetic, overweight and obese patients to patients with heart conditions

SIBO (Small Intestinal Bacterial Overgrowth) is a digestive condition caused by an excessive amount of bacteria in the small intestine

CagriSema produced unprecedented mean weight loss of 20.4% at 68 weeks on an intent-to-treat basis, significantly exceeding semaglutide alone (14.9%), cagrilintide alone (11.5%), and placebo (3.0%)